KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Net Margin (2017 - 2025)

Biomarin Pharmaceutical's Net Margin history spans 16 years, with the latest figure at 5.33% for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 2204.0% year-over-year to 5.33%, compared with a TTM value of 10.83% through Dec 2025, down 413.0%, and an annual FY2025 reading of 10.83%, down 413.0% over the prior year.
  • Net Margin for Q4 2025 was 5.33% at Biomarin Pharmaceutical, down from 3.96% in the prior quarter.
  • The five-year high for Net Margin was 29.14% in Q2 2025, with the low at 12.87% in Q4 2021.
  • Average Net Margin over 5 years is 7.2%, with a median of 6.06% recorded in 2022.
  • Year-over-year, Net Margin tumbled -17353bps in 2021 and then surged 1968bps in 2022.
  • Tracing BMRN's Net Margin over 5 years: stood at 12.87% in 2021, then skyrocketed by 100bps to 0.05% in 2022, then surged by 6907bps to 3.15% in 2023, then surged by 430bps to 16.72% in 2024, then tumbled by -132bps to 5.33% in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Net Margin are 5.33% (Q4 2025), 3.96% (Q3 2025), and 29.14% (Q2 2025).